<data>
<row _id="1"><id>1</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>48136</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="2"><id>2</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1710</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="3"><id>3</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>32093</NumberResult><PercentageResult>69.13</PercentageResult></row>
<row _id="4"><id>4</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>5148</NumberResult><PercentageResult>11.09</PercentageResult></row>
<row _id="5"><id>5</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>117</NumberResult><PercentageResult>0.25</PercentageResult></row>
<row _id="6"><id>6</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>6459</NumberResult><PercentageResult>13.91</PercentageResult></row>
<row _id="7"><id>7</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>1621</NumberResult><PercentageResult>3.49</PercentageResult></row>
<row _id="8"><id>8</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>821</NumberResult><PercentageResult>1.77</PercentageResult></row>
<row _id="9"><id>9</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>76</NumberResult><PercentageResult>0.16</PercentageResult></row>
<row _id="10"><id>10</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>85</NumberResult><PercentageResult>0.18</PercentageResult></row>
<row _id="11"><id>11</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0.01</PercentageResult></row>
<row _id="12"><id>12</id><FinancialYear>2021/22</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="13"><id>13</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24589</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="14"><id>14</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1039</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="15"><id>15</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>15767</NumberResult><PercentageResult>66.95</PercentageResult></row>
<row _id="16"><id>16</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2256</NumberResult><PercentageResult>9.58</PercentageResult></row>
<row _id="17"><id>17</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>68</NumberResult><PercentageResult>0.29</PercentageResult></row>
<row _id="18"><id>18</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4145</NumberResult><PercentageResult>17.6</PercentageResult></row>
<row _id="19"><id>19</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>938</NumberResult><PercentageResult>3.98</PercentageResult></row>
<row _id="20"><id>20</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>307</NumberResult><PercentageResult>1.3</PercentageResult></row>
<row _id="21"><id>21</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0.08</PercentageResult></row>
<row _id="22"><id>22</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>50</NumberResult><PercentageResult>0.21</PercentageResult></row>
<row _id="23"><id>23</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="24"><id>24</id><FinancialYear>2021/22</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="25"><id>25</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23547</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="26"><id>26</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>671</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="27"><id>27</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>16326</NumberResult><PercentageResult>71.37</PercentageResult></row>
<row _id="28"><id>28</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2892</NumberResult><PercentageResult>12.64</PercentageResult></row>
<row _id="29"><id>29</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>49</NumberResult><PercentageResult>0.21</PercentageResult></row>
<row _id="30"><id>30</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2314</NumberResult><PercentageResult>10.12</PercentageResult></row>
<row _id="31"><id>31</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>683</NumberResult><PercentageResult>2.99</PercentageResult></row>
<row _id="32"><id>32</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>514</NumberResult><PercentageResult>2.25</PercentageResult></row>
<row _id="33"><id>33</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>58</NumberResult><PercentageResult>0.25</PercentageResult></row>
<row _id="34"><id>34</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>35</NumberResult><PercentageResult>0.15</PercentageResult></row>
<row _id="35"><id>35</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0.02</PercentageResult></row>
<row _id="36"><id>36</id><FinancialYear>2021/22</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="37"><id>37</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>40665</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="38"><id>38</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1195</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="39"><id>39</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>25653</NumberResult><PercentageResult>65</PercentageResult></row>
<row _id="40"><id>40</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>5116</NumberResult><PercentageResult>13</PercentageResult></row>
<row _id="41"><id>41</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>119</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="42"><id>42</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>6534</NumberResult><PercentageResult>16.6</PercentageResult></row>
<row _id="43"><id>43</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>1272</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="44"><id>44</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>628</NumberResult><PercentageResult>1.6</PercentageResult></row>
<row _id="45"><id>45</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>56</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="46"><id>46</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>88</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="47"><id>47</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="48"><id>48</id><FinancialYear>2020/21</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="49"><id>49</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>20819</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="50"><id>50</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>724</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="51"><id>51</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>12376</NumberResult><PercentageResult>61.6</PercentageResult></row>
<row _id="52"><id>52</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2388</NumberResult><PercentageResult>11.9</PercentageResult></row>
<row _id="53"><id>53</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>57</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="54"><id>54</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4196</NumberResult><PercentageResult>20.9</PercentageResult></row>
<row _id="55"><id>55</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>745</NumberResult><PercentageResult>3.7</PercentageResult></row>
<row _id="56"><id>56</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>273</NumberResult><PercentageResult>1.4</PercentageResult></row>
<row _id="57"><id>57</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="58"><id>58</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>45</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="59"><id>59</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="60"><id>60</id><FinancialYear>2020/21</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="61"><id>61</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>19846</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="62"><id>62</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>471</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="63"><id>63</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>13277</NumberResult><PercentageResult>68.5</PercentageResult></row>
<row _id="64"><id>64</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2728</NumberResult><PercentageResult>14.1</PercentageResult></row>
<row _id="65"><id>65</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>62</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="66"><id>66</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2338</NumberResult><PercentageResult>12.1</PercentageResult></row>
<row _id="67"><id>67</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>527</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="68"><id>68</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>355</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="69"><id>69</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>41</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="70"><id>70</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>43</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="71"><id>71</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="72"><id>72</id><FinancialYear>2020/21</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="73"><id>73</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>318727</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="74"><id>74</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>7930</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="75"><id>75</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>285139</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="76"><id>76</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>12135</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="77"><id>77</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>494</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="78"><id>78</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>10067</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="79"><id>79</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>1567</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="80"><id>80</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>1163</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="81"><id>81</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>93</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="82"><id>82</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>114</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="83"><id>83</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="84"><id>84</id><FinancialYear>2019/20</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="85"><id>85</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>20594</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="86"><id>86</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>621</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="87"><id>87</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>18417</NumberResult><PercentageResult>92.2</PercentageResult></row>
<row _id="88"><id>88</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>551</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="89"><id>89</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="90"><id>90</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>765</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="91"><id>91</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>136</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="92"><id>92</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>70</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="93"><id>93</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="94"><id>94</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="95"><id>95</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="96"><id>96</id><FinancialYear>2019/20</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="97"><id>97</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>18576</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="98"><id>98</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>459</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="99"><id>99</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>16376</NumberResult><PercentageResult>90.4</PercentageResult></row>
<row _id="100"><id>100</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>767</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="101"><id>101</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>56</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="102"><id>102</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>681</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="103"><id>103</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>151</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="104"><id>104</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>62</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="105"><id>105</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="106"><id>106</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="107"><id>107</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="108"><id>108</id><FinancialYear>2019/20</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="109"><id>109</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>51499</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="110"><id>110</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>949</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="111"><id>111</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>46676</NumberResult><PercentageResult>92.3</PercentageResult></row>
<row _id="112"><id>112</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1626</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="113"><id>113</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="114"><id>114</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1813</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="115"><id>115</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>230</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="116"><id>116</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>153</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="117"><id>117</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="118"><id>118</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="119"><id>119</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="120"><id>120</id><FinancialYear>2019/20</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="121"><id>121</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>81505</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="122"><id>122</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2364</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="123"><id>123</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>70684</NumberResult><PercentageResult>89.3</PercentageResult></row>
<row _id="124"><id>124</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>4081</NumberResult><PercentageResult>5.2</PercentageResult></row>
<row _id="125"><id>125</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>191</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="126"><id>126</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>3422</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="127"><id>127</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>415</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="128"><id>128</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>308</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="129"><id>129</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="130"><id>130</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="131"><id>131</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="132"><id>132</id><FinancialYear>2019/20</FinancialYear><HBT>S08000031</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="133"><id>133</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>61164</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="134"><id>134</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1808</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="135"><id>135</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>55799</NumberResult><PercentageResult>94</PercentageResult></row>
<row _id="136"><id>136</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1952</NumberResult><PercentageResult>3.3</PercentageResult></row>
<row _id="137"><id>137</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>52</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="138"><id>138</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1067</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="139"><id>139</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>252</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="140"><id>140</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>185</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="141"><id>141</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="142"><id>142</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="143"><id>143</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="144"><id>144</id><FinancialYear>2019/20</FinancialYear><HBT>S08000032</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="145"><id>145</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>62553</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="146"><id>146</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1075</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="147"><id>147</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>56385</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="148"><id>148</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2637</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="149"><id>149</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>118</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="150"><id>150</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1725</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="151"><id>151</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>288</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="152"><id>152</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>274</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="153"><id>153</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>26</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="154"><id>154</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>21</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="155"><id>155</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="156"><id>156</id><FinancialYear>2019/20</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="157"><id>157</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>22836</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="158"><id>158</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>654</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="159"><id>159</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20802</NumberResult><PercentageResult>93.8</PercentageResult></row>
<row _id="160"><id>160</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>521</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="161"><id>161</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>38</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="162"><id>162</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>594</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="163"><id>163</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>95</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="164"><id>164</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>111</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="165"><id>165</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="166"><id>166</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="167"><id>167</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="168"><id>168</id><FinancialYear>2019/20</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="169"><id>169</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>407854</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="170"><id>170</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10753</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="171"><id>171</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>365085</NumberResult><PercentageResult>91.9</PercentageResult></row>
<row _id="172"><id>172</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>15203</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="173"><id>173</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>652</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="174"><id>174</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>12211</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="175"><id>175</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2054</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="176"><id>176</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>1555</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="177"><id>177</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>110</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="178"><id>178</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>188</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="179"><id>179</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="180"><id>180</id><FinancialYear>2018/19</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>33</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="181"><id>181</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25448</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="182"><id>182</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>672</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="183"><id>183</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>23111</NumberResult><PercentageResult>93.3</PercentageResult></row>
<row _id="184"><id>184</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>595</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="185"><id>185</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="186"><id>186</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>789</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="187"><id>187</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>145</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="188"><id>188</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>91</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="189"><id>189</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="190"><id>190</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="191"><id>191</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="192"><id>192</id><FinancialYear>2018/19</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="193"><id>193</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23074</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="194"><id>194</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>521</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="195"><id>195</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20529</NumberResult><PercentageResult>91</PercentageResult></row>
<row _id="196"><id>196</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>925</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="197"><id>197</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>94</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="198"><id>198</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>716</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="199"><id>199</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>172</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="200"><id>200</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>85</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="201"><id>201</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="202"><id>202</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>21</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="203"><id>203</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="204"><id>204</id><FinancialYear>2018/19</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="205"><id>205</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>64663</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="206"><id>206</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1274</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="207"><id>207</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>58594</NumberResult><PercentageResult>92.4</PercentageResult></row>
<row _id="208"><id>208</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2206</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="209"><id>209</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>34</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="210"><id>210</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2043</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="211"><id>211</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>251</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="212"><id>212</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>224</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="213"><id>213</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="214"><id>214</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="215"><id>215</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="216"><id>216</id><FinancialYear>2018/19</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="217"><id>217</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>103942</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="218"><id>218</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2979</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="219"><id>219</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>90793</NumberResult><PercentageResult>89.9</PercentageResult></row>
<row _id="220"><id>220</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>4645</NumberResult><PercentageResult>4.6</PercentageResult></row>
<row _id="221"><id>221</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>237</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="222"><id>222</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4138</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="223"><id>223</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>644</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="224"><id>224</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>422</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="225"><id>225</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="226"><id>226</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>56</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="227"><id>227</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="228"><id>228</id><FinancialYear>2018/19</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="229"><id>229</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>81518</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="230"><id>230</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2938</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="231"><id>231</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>74125</NumberResult><PercentageResult>94.3</PercentageResult></row>
<row _id="232"><id>232</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2127</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="233"><id>233</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>63</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="234"><id>234</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1630</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="235"><id>235</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>331</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="236"><id>236</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>237</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="237"><id>237</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="238"><id>238</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>33</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="239"><id>239</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="240"><id>240</id><FinancialYear>2018/19</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="241"><id>241</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>78776</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="242"><id>242</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1473</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="243"><id>243</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>70402</NumberResult><PercentageResult>91.1</PercentageResult></row>
<row _id="244"><id>244</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3889</NumberResult><PercentageResult>5</PercentageResult></row>
<row _id="245"><id>245</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>158</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="246"><id>246</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2077</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="247"><id>247</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>377</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="248"><id>248</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>332</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="249"><id>249</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="250"><id>250</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>26</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="251"><id>251</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="252"><id>252</id><FinancialYear>2018/19</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="253"><id>253</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>30433</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="254"><id>254</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>896</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="255"><id>255</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>27531</NumberResult><PercentageResult>93.2</PercentageResult></row>
<row _id="256"><id>256</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>816</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="257"><id>257</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>48</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="258"><id>258</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>818</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="259"><id>259</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>134</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="260"><id>260</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>164</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="261"><id>261</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="262"><id>262</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="263"><id>263</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="264"><id>264</id><FinancialYear>2018/19</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="265"><id>265</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>378382</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="266"><id>266</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10561</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="267"><id>267</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>337493</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="268"><id>268</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>14135</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="269"><id>269</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>454</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="270"><id>270</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>11783</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="271"><id>271</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2055</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="272"><id>272</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>1569</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="273"><id>273</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>94</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="274"><id>274</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>193</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="275"><id>275</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="276"><id>276</id><FinancialYear>2017/18</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>38</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="277"><id>277</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>11559</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="278"><id>278</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>530</NumberResult><PercentageResult>4.6</PercentageResult></row>
<row _id="279"><id>279</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>10129</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="280"><id>280</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>514</NumberResult><PercentageResult>4.7</PercentageResult></row>
<row _id="281"><id>281</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="282"><id>282</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>265</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="283"><id>283</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>26</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="284"><id>284</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>63</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="285"><id>285</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="286"><id>286</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="287"><id>287</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="288"><id>288</id><FinancialYear>2017/18</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="289"><id>289</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24005</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="290"><id>290</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>449</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="291"><id>291</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21864</NumberResult><PercentageResult>92.8</PercentageResult></row>
<row _id="292"><id>292</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>587</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="293"><id>293</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="294"><id>294</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>803</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="295"><id>295</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>170</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="296"><id>296</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>106</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="297"><id>297</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="298"><id>298</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="299"><id>299</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="300"><id>300</id><FinancialYear>2017/18</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="301"><id>301</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>21562</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="302"><id>302</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>376</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="303"><id>303</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>19448</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="304"><id>304</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>820</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="305"><id>305</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>54</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="306"><id>306</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>593</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="307"><id>307</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>151</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="308"><id>308</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>81</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="309"><id>309</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="310"><id>310</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="311"><id>311</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="312"><id>312</id><FinancialYear>2017/18</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="313"><id>313</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>60825</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="314"><id>314</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1494</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="315"><id>315</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>54396</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="316"><id>316</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2121</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="317"><id>317</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>37</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="318"><id>318</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2218</NumberResult><PercentageResult>3.7</PercentageResult></row>
<row _id="319"><id>319</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>283</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="320"><id>320</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>230</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="321"><id>321</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="322"><id>322</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="323"><id>323</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="324"><id>324</id><FinancialYear>2017/18</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="325"><id>325</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>96216</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="326"><id>326</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2796</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="327"><id>327</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>84564</NumberResult><PercentageResult>90.5</PercentageResult></row>
<row _id="328"><id>328</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3801</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="329"><id>329</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>140</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="330"><id>330</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>3821</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="331"><id>331</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>635</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="332"><id>332</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>380</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="333"><id>333</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="334"><id>334</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>50</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="335"><id>335</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="336"><id>336</id><FinancialYear>2017/18</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="337"><id>337</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>63146</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="338"><id>338</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2127</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="339"><id>339</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>56749</NumberResult><PercentageResult>93</PercentageResult></row>
<row _id="340"><id>340</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2332</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="341"><id>341</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>70</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="342"><id>342</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1308</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="343"><id>343</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>291</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="344"><id>344</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>214</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="345"><id>345</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="346"><id>346</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>32</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="347"><id>347</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="348"><id>348</id><FinancialYear>2017/18</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="349"><id>349</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>73107</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="350"><id>350</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2060</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="351"><id>351</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>64832</NumberResult><PercentageResult>91.3</PercentageResult></row>
<row _id="352"><id>352</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3331</NumberResult><PercentageResult>4.7</PercentageResult></row>
<row _id="353"><id>353</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>94</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="354"><id>354</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1977</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="355"><id>355</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>388</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="356"><id>356</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>357</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="357"><id>357</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>32</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="358"><id>358</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="359"><id>359</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="360"><id>360</id><FinancialYear>2017/18</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="361"><id>361</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>27962</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="362"><id>362</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>729</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="363"><id>363</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>25511</NumberResult><PercentageResult>93.7</PercentageResult></row>
<row _id="364"><id>364</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>629</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="365"><id>365</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="366"><id>366</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>798</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="367"><id>367</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>111</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="368"><id>368</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>138</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="369"><id>369</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="370"><id>370</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="371"><id>371</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="372"><id>372</id><FinancialYear>2017/18</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="373"><id>373</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>417267</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="374"><id>374</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>11562</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="375"><id>375</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>371153</NumberResult><PercentageResult>91.5</PercentageResult></row>
<row _id="376"><id>376</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>16475</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="377"><id>377</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>449</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="378"><id>378</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>13380</NumberResult><PercentageResult>3.3</PercentageResult></row>
<row _id="379"><id>379</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2161</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="380"><id>380</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>1781</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="381"><id>381</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>97</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="382"><id>382</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>170</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="383"><id>383</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="384"><id>384</id><FinancialYear>2016/17</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>34</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="385"><id>385</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>27080</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="386"><id>386</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>920</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="387"><id>387</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>23978</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="388"><id>388</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1247</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="389"><id>389</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>34</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="390"><id>390</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>612</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="391"><id>391</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>107</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="392"><id>392</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>158</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="393"><id>393</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="394"><id>394</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="395"><id>395</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="396"><id>396</id><FinancialYear>2016/17</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="397"><id>397</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>26354</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="398"><id>398</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>512</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="399"><id>399</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>23755</NumberResult><PercentageResult>91.9</PercentageResult></row>
<row _id="400"><id>400</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>716</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="401"><id>401</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="402"><id>402</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1062</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="403"><id>403</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>141</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="404"><id>404</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>113</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="405"><id>405</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="406"><id>406</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="407"><id>407</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="408"><id>408</id><FinancialYear>2016/17</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="409"><id>409</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24713</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="410"><id>410</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>640</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="411"><id>411</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22118</NumberResult><PercentageResult>91.9</PercentageResult></row>
<row _id="412"><id>412</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>985</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="413"><id>413</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>34</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="414"><id>414</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>671</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="415"><id>415</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>160</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="416"><id>416</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>79</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="417"><id>417</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="418"><id>418</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="419"><id>419</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="420"><id>420</id><FinancialYear>2016/17</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="421"><id>421</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>68910</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="422"><id>422</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1759</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="423"><id>423</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>61470</NumberResult><PercentageResult>91.5</PercentageResult></row>
<row _id="424"><id>424</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2571</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="425"><id>425</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="426"><id>426</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2543</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="427"><id>427</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>255</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="428"><id>428</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>247</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="429"><id>429</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="430"><id>430</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="431"><id>431</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="432"><id>432</id><FinancialYear>2016/17</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="433"><id>433</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>103788</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="434"><id>434</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>3142</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="435"><id>435</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>90521</NumberResult><PercentageResult>89.9</PercentageResult></row>
<row _id="436"><id>436</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>4576</NumberResult><PercentageResult>4.5</PercentageResult></row>
<row _id="437"><id>437</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>178</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="438"><id>438</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4201</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="439"><id>439</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>692</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="440"><id>440</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>414</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="441"><id>441</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="442"><id>442</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>38</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="443"><id>443</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="444"><id>444</id><FinancialYear>2016/17</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="445"><id>445</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>55254</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="446"><id>446</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1590</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="447"><id>447</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>49902</NumberResult><PercentageResult>93</PercentageResult></row>
<row _id="448"><id>448</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2166</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="449"><id>449</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>47</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="450"><id>450</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1047</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="451"><id>451</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>276</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="452"><id>452</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>182</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="453"><id>453</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="454"><id>454</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="455"><id>455</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="456"><id>456</id><FinancialYear>2016/17</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="457"><id>457</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>79931</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="458"><id>458</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2395</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="459"><id>459</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>70860</NumberResult><PercentageResult>91.4</PercentageResult></row>
<row _id="460"><id>460</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3483</NumberResult><PercentageResult>4.5</PercentageResult></row>
<row _id="461"><id>461</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>80</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="462"><id>462</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2202</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="463"><id>463</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>402</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="464"><id>464</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>441</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="465"><id>465</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>32</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="466"><id>466</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="467"><id>467</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="468"><id>468</id><FinancialYear>2016/17</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="469"><id>469</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>31237</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="470"><id>470</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>604</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="471"><id>471</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>28549</NumberResult><PercentageResult>93.2</PercentageResult></row>
<row _id="472"><id>472</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>731</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="473"><id>473</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>19</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="474"><id>474</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1042</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="475"><id>475</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>128</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="476"><id>476</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>147</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="477"><id>477</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="478"><id>478</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="479"><id>479</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="480"><id>480</id><FinancialYear>2016/17</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="481"><id>481</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>399150</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="482"><id>482</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10146</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="483"><id>483</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>353225</NumberResult><PercentageResult>90.8</PercentageResult></row>
<row _id="484"><id>484</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>16328</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="485"><id>485</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>395</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="486"><id>486</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>14180</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="487"><id>487</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2474</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="488"><id>488</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>2095</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="489"><id>489</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>82</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="490"><id>490</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>197</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="491"><id>491</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="492"><id>492</id><FinancialYear>2015/16</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="493"><id>493</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25759</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="494"><id>494</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>795</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="495"><id>495</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22883</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="496"><id>496</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1225</NumberResult><PercentageResult>4.9</PercentageResult></row>
<row _id="497"><id>497</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="498"><id>498</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>557</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="499"><id>499</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>93</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="500"><id>500</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>171</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="501"><id>501</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="502"><id>502</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="503"><id>503</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="504"><id>504</id><FinancialYear>2015/16</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="505"><id>505</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25488</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="506"><id>506</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>579</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="507"><id>507</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22644</NumberResult><PercentageResult>90.9</PercentageResult></row>
<row _id="508"><id>508</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>754</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="509"><id>509</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>26</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="510"><id>510</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1137</NumberResult><PercentageResult>4.6</PercentageResult></row>
<row _id="511"><id>511</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>184</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="512"><id>512</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>136</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="513"><id>513</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="514"><id>514</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>21</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="515"><id>515</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="516"><id>516</id><FinancialYear>2015/16</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="517"><id>517</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23236</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="518"><id>518</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>713</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="519"><id>519</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20281</NumberResult><PercentageResult>90</PercentageResult></row>
<row _id="520"><id>520</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1180</NumberResult><PercentageResult>5.2</PercentageResult></row>
<row _id="521"><id>521</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>45</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="522"><id>522</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>703</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="523"><id>523</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>190</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="524"><id>524</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>94</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="525"><id>525</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="526"><id>526</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="527"><id>527</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="528"><id>528</id><FinancialYear>2015/16</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="529"><id>529</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>65685</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="530"><id>530</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1482</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="531"><id>531</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>57899</NumberResult><PercentageResult>90.2</PercentageResult></row>
<row _id="532"><id>532</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2785</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="533"><id>533</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="534"><id>534</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2851</NumberResult><PercentageResult>4.4</PercentageResult></row>
<row _id="535"><id>535</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>316</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="536"><id>536</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>290</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="537"><id>537</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="538"><id>538</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>25</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="539"><id>539</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="540"><id>540</id><FinancialYear>2015/16</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="541"><id>541</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>99037</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="542"><id>542</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2755</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="543"><id>543</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>87024</NumberResult><PercentageResult>90.4</PercentageResult></row>
<row _id="544"><id>544</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3707</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="545"><id>545</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>132</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="546"><id>546</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4117</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="547"><id>547</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>704</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="548"><id>548</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>529</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="549"><id>549</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="550"><id>550</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>46</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="551"><id>551</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="552"><id>552</id><FinancialYear>2015/16</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="553"><id>553</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>52565</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="554"><id>554</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1016</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="555"><id>555</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>47763</NumberResult><PercentageResult>92.7</PercentageResult></row>
<row _id="556"><id>556</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2085</NumberResult><PercentageResult>4</PercentageResult></row>
<row _id="557"><id>557</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>39</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="558"><id>558</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1149</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="559"><id>559</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>300</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="560"><id>560</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>173</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="561"><id>561</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="562"><id>562</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>25</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="563"><id>563</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="564"><id>564</id><FinancialYear>2015/16</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="565"><id>565</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>77408</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="566"><id>566</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2217</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="567"><id>567</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>67786</NumberResult><PercentageResult>90.2</PercentageResult></row>
<row _id="568"><id>568</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3646</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="569"><id>569</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>76</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="570"><id>570</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2535</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="571"><id>571</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>529</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="572"><id>572</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>547</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="573"><id>573</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="574"><id>574</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>41</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="575"><id>575</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="576"><id>576</id><FinancialYear>2015/16</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="577"><id>577</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>29972</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="578"><id>578</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>589</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="579"><id>579</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>26945</NumberResult><PercentageResult>91.7</PercentageResult></row>
<row _id="580"><id>580</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>946</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="581"><id>581</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>21</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="582"><id>582</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1131</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="583"><id>583</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>158</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="584"><id>584</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>155</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="585"><id>585</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="586"><id>586</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="587"><id>587</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="588"><id>588</id><FinancialYear>2015/16</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="589"><id>589</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>397673</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="590"><id>590</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10665</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="591"><id>591</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>351995</NumberResult><PercentageResult>91</PercentageResult></row>
<row _id="592"><id>592</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>15838</NumberResult><PercentageResult>4.1</PercentageResult></row>
<row _id="593"><id>593</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>385</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="594"><id>594</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>13612</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="595"><id>595</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2636</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="596"><id>596</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>2247</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="597"><id>597</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>79</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="598"><id>598</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>186</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="599"><id>599</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="600"><id>600</id><FinancialYear>2014/15</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>22</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="601"><id>601</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25319</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="602"><id>602</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>903</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="603"><id>603</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22104</NumberResult><PercentageResult>90.5</PercentageResult></row>
<row _id="604"><id>604</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1350</NumberResult><PercentageResult>5.5</PercentageResult></row>
<row _id="605"><id>605</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>48</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="606"><id>606</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>559</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="607"><id>607</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>123</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="608"><id>608</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>212</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="609"><id>609</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="610"><id>610</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="611"><id>611</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="612"><id>612</id><FinancialYear>2014/15</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="613"><id>613</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24822</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="614"><id>614</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>415</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="615"><id>615</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>22409</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="616"><id>616</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>590</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="617"><id>617</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="618"><id>618</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1064</NumberResult><PercentageResult>4.4</PercentageResult></row>
<row _id="619"><id>619</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>177</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="620"><id>620</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>133</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="621"><id>621</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="622"><id>622</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="623"><id>623</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="624"><id>624</id><FinancialYear>2014/15</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="625"><id>625</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>22758</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="626"><id>626</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>524</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="627"><id>627</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>19908</NumberResult><PercentageResult>89.5</PercentageResult></row>
<row _id="628"><id>628</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1164</NumberResult><PercentageResult>5.2</PercentageResult></row>
<row _id="629"><id>629</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>66</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="630"><id>630</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>699</NumberResult><PercentageResult>3.1</PercentageResult></row>
<row _id="631"><id>631</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>234</NumberResult><PercentageResult>1.1</PercentageResult></row>
<row _id="632"><id>632</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>124</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="633"><id>633</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="634"><id>634</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="635"><id>635</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="636"><id>636</id><FinancialYear>2014/15</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="637"><id>637</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>59706</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="638"><id>638</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1277</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="639"><id>639</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>52995</NumberResult><PercentageResult>90.7</PercentageResult></row>
<row _id="640"><id>640</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2504</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="641"><id>641</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>31</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="642"><id>642</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2267</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="643"><id>643</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>345</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="644"><id>644</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>250</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="645"><id>645</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="646"><id>646</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>22</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="647"><id>647</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="648"><id>648</id><FinancialYear>2014/15</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="649"><id>649</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>101000</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="650"><id>650</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2297</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="651"><id>651</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>89172</NumberResult><PercentageResult>90.3</PercentageResult></row>
<row _id="652"><id>652</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3774</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="653"><id>653</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>98</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="654"><id>654</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4251</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="655"><id>655</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>800</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="656"><id>656</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>539</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="657"><id>657</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="658"><id>658</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>41</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="659"><id>659</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="660"><id>660</id><FinancialYear>2014/15</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="661"><id>661</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>4598</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="662"><id>662</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>119</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="663"><id>663</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>4166</NumberResult><PercentageResult>93</PercentageResult></row>
<row _id="664"><id>664</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>105</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="665"><id>665</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="666"><id>666</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>135</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="667"><id>667</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>28</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="668"><id>668</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>37</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="669"><id>669</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="670"><id>670</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="671"><id>671</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="672"><id>672</id><FinancialYear>2014/15</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="673"><id>673</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>51793</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="674"><id>674</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>967</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="675"><id>675</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>47255</NumberResult><PercentageResult>93</PercentageResult></row>
<row _id="676"><id>676</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1920</NumberResult><PercentageResult>3.8</PercentageResult></row>
<row _id="677"><id>677</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>38</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="678"><id>678</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1087</NumberResult><PercentageResult>2.1</PercentageResult></row>
<row _id="679"><id>679</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>275</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="680"><id>680</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>218</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="681"><id>681</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="682"><id>682</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>22</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="683"><id>683</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="684"><id>684</id><FinancialYear>2014/15</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="685"><id>685</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>78163</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="686"><id>686</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>3608</NumberResult><PercentageResult>4.6</PercentageResult></row>
<row _id="687"><id>687</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>67354</NumberResult><PercentageResult>90.3</PercentageResult></row>
<row _id="688"><id>688</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3437</NumberResult><PercentageResult>4.6</PercentageResult></row>
<row _id="689"><id>689</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>70</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="690"><id>690</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2550</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="691"><id>691</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>492</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="692"><id>692</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>593</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="693"><id>693</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="694"><id>694</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>37</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="695"><id>695</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="696"><id>696</id><FinancialYear>2014/15</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="697"><id>697</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>29514</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="698"><id>698</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>555</NumberResult><PercentageResult>1.9</PercentageResult></row>
<row _id="699"><id>699</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>26632</NumberResult><PercentageResult>92</PercentageResult></row>
<row _id="700"><id>700</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>994</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="701"><id>701</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="702"><id>702</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1000</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="703"><id>703</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>162</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="704"><id>704</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>141</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="705"><id>705</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="706"><id>706</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="707"><id>707</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="708"><id>708</id><FinancialYear>2014/15</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="709"><id>709</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>384296</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="710"><id>710</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10249</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="711"><id>711</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>338850</NumberResult><PercentageResult>90.6</PercentageResult></row>
<row _id="712"><id>712</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>16026</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="713"><id>713</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>304</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="714"><id>714</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>13575</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="715"><id>715</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2755</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="716"><id>716</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>2245</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="717"><id>717</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>97</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="718"><id>718</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>162</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="719"><id>719</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="720"><id>720</id><FinancialYear>2013/14</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="721"><id>721</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24072</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="722"><id>722</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>548</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="723"><id>723</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21365</NumberResult><PercentageResult>90.8</PercentageResult></row>
<row _id="724"><id>724</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1375</NumberResult><PercentageResult>5.8</PercentageResult></row>
<row _id="725"><id>725</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="726"><id>726</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>469</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="727"><id>727</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>106</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="728"><id>728</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>179</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="729"><id>729</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="730"><id>730</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="731"><id>731</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="732"><id>732</id><FinancialYear>2013/14</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="733"><id>733</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>24126</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="734"><id>734</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>334</NumberResult><PercentageResult>1.4</PercentageResult></row>
<row _id="735"><id>735</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>21778</NumberResult><PercentageResult>91.5</PercentageResult></row>
<row _id="736"><id>736</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>706</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="737"><id>737</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="738"><id>738</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1005</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="739"><id>739</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>166</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="740"><id>740</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>103</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="741"><id>741</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="742"><id>742</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="743"><id>743</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="744"><id>744</id><FinancialYear>2013/14</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="745"><id>745</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>22200</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="746"><id>746</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>574</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="747"><id>747</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>19433</NumberResult><PercentageResult>89.9</PercentageResult></row>
<row _id="748"><id>748</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1136</NumberResult><PercentageResult>5.3</PercentageResult></row>
<row _id="749"><id>749</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>49</NumberResult><PercentageResult>0.2</PercentageResult></row>
<row _id="750"><id>750</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>686</NumberResult><PercentageResult>3.2</PercentageResult></row>
<row _id="751"><id>751</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>192</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="752"><id>752</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>105</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="753"><id>753</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="754"><id>754</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="755"><id>755</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="756"><id>756</id><FinancialYear>2013/14</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="757"><id>757</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>44864</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="758"><id>758</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1161</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="759"><id>759</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>39298</NumberResult><PercentageResult>89.9</PercentageResult></row>
<row _id="760"><id>760</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2016</NumberResult><PercentageResult>4.6</PercentageResult></row>
<row _id="761"><id>761</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>22</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="762"><id>762</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1838</NumberResult><PercentageResult>4.2</PercentageResult></row>
<row _id="763"><id>763</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>270</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="764"><id>764</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>229</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="765"><id>765</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="766"><id>766</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="767"><id>767</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="768"><id>768</id><FinancialYear>2013/14</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="769"><id>769</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>98959</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="770"><id>770</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2787</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="771"><id>771</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>86280</NumberResult><PercentageResult>89.7</PercentageResult></row>
<row _id="772"><id>772</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>4132</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="773"><id>773</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>69</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="774"><id>774</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>4298</NumberResult><PercentageResult>4.5</PercentageResult></row>
<row _id="775"><id>775</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>820</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="776"><id>776</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>507</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="777"><id>777</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>24</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="778"><id>778</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>36</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="779"><id>779</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="780"><id>780</id><FinancialYear>2013/14</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="781"><id>781</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>16717</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="782"><id>782</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>377</NumberResult><PercentageResult>2.3</PercentageResult></row>
<row _id="783"><id>783</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>15004</NumberResult><PercentageResult>91.8</PercentageResult></row>
<row _id="784"><id>784</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>435</NumberResult><PercentageResult>2.7</PercentageResult></row>
<row _id="785"><id>785</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>15</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="786"><id>786</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>570</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="787"><id>787</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>118</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="788"><id>788</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>170</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="789"><id>789</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="790"><id>790</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>9</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="791"><id>791</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="792"><id>792</id><FinancialYear>2013/14</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="793"><id>793</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>50295</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="794"><id>794</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1216</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="795"><id>795</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>45523</NumberResult><PercentageResult>92.8</PercentageResult></row>
<row _id="796"><id>796</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1907</NumberResult><PercentageResult>3.9</PercentageResult></row>
<row _id="797"><id>797</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="798"><id>798</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1079</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="799"><id>799</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>315</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="800"><id>800</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>197</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="801"><id>801</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="802"><id>802</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="803"><id>803</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="804"><id>804</id><FinancialYear>2013/14</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="805"><id>805</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>75211</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="806"><id>806</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2537</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="807"><id>807</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>65168</NumberResult><PercentageResult>89.7</PercentageResult></row>
<row _id="808"><id>808</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>3504</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="809"><id>809</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>82</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="810"><id>810</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2685</NumberResult><PercentageResult>3.7</PercentageResult></row>
<row _id="811"><id>811</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>614</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="812"><id>812</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>571</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="813"><id>813</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="814"><id>814</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>29</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="815"><id>815</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="816"><id>816</id><FinancialYear>2013/14</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="817"><id>817</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>27852</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="818"><id>818</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>715</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="819"><id>819</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>25001</NumberResult><PercentageResult>92.1</PercentageResult></row>
<row _id="820"><id>820</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>815</NumberResult><PercentageResult>3</PercentageResult></row>
<row _id="821"><id>821</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>14</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="822"><id>822</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>945</NumberResult><PercentageResult>3.5</PercentageResult></row>
<row _id="823"><id>823</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>154</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="824"><id>824</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>184</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="825"><id>825</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="826"><id>826</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="827"><id>827</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="828"><id>828</id><FinancialYear>2013/14</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="829"><id>829</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>405020</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="830"><id>830</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>10025</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="831"><id>831</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Negative</Results><ResultsQF /><NumberResult>356513</NumberResult><PercentageResult>90.3</PercentageResult></row>
<row _id="832"><id>832</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>22776</NumberResult><PercentageResult>5.8</PercentageResult></row>
<row _id="833"><id>833</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>344</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="834"><id>834</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>9840</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="835"><id>835</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>2919</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="836"><id>836</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>2320</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="837"><id>837</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>84</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="838"><id>838</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>158</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="839"><id>839</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>8</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="840"><id>840</id><FinancialYear>2012/13</FinancialYear><HBT>S92000003</HBT><HBTQF>d</HBTQF><Laboratory>Scotland</Laboratory><LaboratoryQF>d</LaboratoryQF><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>33</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="841"><id>841</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25440</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="842"><id>842</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>569</NumberResult><PercentageResult>2.2</PercentageResult></row>
<row _id="843"><id>843</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>23296</NumberResult><PercentageResult>93.7</PercentageResult></row>
<row _id="844"><id>844</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1067</NumberResult><PercentageResult>4.3</PercentageResult></row>
<row _id="845"><id>845</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>18</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="846"><id>846</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>233</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="847"><id>847</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>66</NumberResult><PercentageResult>0.3</PercentageResult></row>
<row _id="848"><id>848</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>183</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="849"><id>849</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="850"><id>850</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="851"><id>851</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="852"><id>852</id><FinancialYear>2012/13</FinancialYear><HBT>S08000015</HBT><HBTQF /><Laboratory>Cross House</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="853"><id>853</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>25824</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="854"><id>854</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>457</NumberResult><PercentageResult>1.8</PercentageResult></row>
<row _id="855"><id>855</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>23506</NumberResult><PercentageResult>92.7</PercentageResult></row>
<row _id="856"><id>856</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>941</NumberResult><PercentageResult>3.7</PercentageResult></row>
<row _id="857"><id>857</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="858"><id>858</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>639</NumberResult><PercentageResult>2.5</PercentageResult></row>
<row _id="859"><id>859</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>155</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="860"><id>860</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>103</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="861"><id>861</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>4</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="862"><id>862</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>10</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="863"><id>863</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="864"><id>864</id><FinancialYear>2012/13</FinancialYear><HBT>S08000029</HBT><HBTQF /><Laboratory>Forth Park</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="865"><id>865</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>23161</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="866"><id>866</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>761</NumberResult><PercentageResult>3.3</PercentageResult></row>
<row _id="867"><id>867</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>20602</NumberResult><PercentageResult>92</PercentageResult></row>
<row _id="868"><id>868</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1115</NumberResult><PercentageResult>5</PercentageResult></row>
<row _id="869"><id>869</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="870"><id>870</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>390</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="871"><id>871</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>157</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="872"><id>872</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>92</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="873"><id>873</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="874"><id>874</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="875"><id>875</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="876"><id>876</id><FinancialYear>2012/13</FinancialYear><HBT>S08000019</HBT><HBTQF /><Laboratory>Stirling Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="877"><id>877</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>46470</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="878"><id>878</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>912</NumberResult><PercentageResult>2</PercentageResult></row>
<row _id="879"><id>879</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>41278</NumberResult><PercentageResult>90.6</PercentageResult></row>
<row _id="880"><id>880</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2620</NumberResult><PercentageResult>5.8</PercentageResult></row>
<row _id="881"><id>881</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>20</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="882"><id>882</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>1114</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="883"><id>883</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>268</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="884"><id>884</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>228</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="885"><id>885</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>7</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="886"><id>886</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="887"><id>887</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="888"><id>888</id><FinancialYear>2012/13</FinancialYear><HBT>S08000020</HBT><HBTQF /><Laboratory>Forester Hill</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="889"><id>889</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>104507</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="890"><id>890</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>3032</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="891"><id>891</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>87941</NumberResult><PercentageResult>86.7</PercentageResult></row>
<row _id="892"><id>892</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>8174</NumberResult><PercentageResult>8.1</PercentageResult></row>
<row _id="893"><id>893</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>124</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="894"><id>894</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>3416</NumberResult><PercentageResult>3.4</PercentageResult></row>
<row _id="895"><id>895</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>1006</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="896"><id>896</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>716</NumberResult><PercentageResult>0.7</PercentageResult></row>
<row _id="897"><id>897</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="898"><id>898</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>63</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="899"><id>899</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>0</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="900"><id>900</id><FinancialYear>2012/13</FinancialYear><HBT>S08000021</HBT><HBTQF /><Laboratory>Southern General</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>12</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="901"><id>901</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>17418</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="902"><id>902</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>214</NumberResult><PercentageResult>1.2</PercentageResult></row>
<row _id="903"><id>903</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>16026</NumberResult><PercentageResult>93.2</PercentageResult></row>
<row _id="904"><id>904</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>446</NumberResult><PercentageResult>2.6</PercentageResult></row>
<row _id="905"><id>905</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>17</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="906"><id>906</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>407</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="907"><id>907</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>131</NumberResult><PercentageResult>0.8</PercentageResult></row>
<row _id="908"><id>908</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>150</NumberResult><PercentageResult>0.9</PercentageResult></row>
<row _id="909"><id>909</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>13</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="910"><id>910</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="911"><id>911</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="912"><id>912</id><FinancialYear>2012/13</FinancialYear><HBT>S08000022</HBT><HBTQF /><Laboratory>Raigmore</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="913"><id>913</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>53979</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="914"><id>914</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>1294</NumberResult><PercentageResult>2.4</PercentageResult></row>
<row _id="915"><id>915</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>49009</NumberResult><PercentageResult>93</PercentageResult></row>
<row _id="916"><id>916</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>2513</NumberResult><PercentageResult>4.8</PercentageResult></row>
<row _id="917"><id>917</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>27</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="918"><id>918</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>657</NumberResult><PercentageResult>1.2</PercentageResult></row>
<row _id="919"><id>919</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>245</NumberResult><PercentageResult>0.5</PercentageResult></row>
<row _id="920"><id>920</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>197</NumberResult><PercentageResult>0.4</PercentageResult></row>
<row _id="921"><id>921</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="922"><id>922</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>23</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="923"><id>923</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="924"><id>924</id><FinancialYear>2012/13</FinancialYear><HBT>S08000023</HBT><HBTQF /><Laboratory>Monklands</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="925"><id>925</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>78879</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="926"><id>926</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>2286</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="927"><id>927</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>68226</NumberResult><PercentageResult>89.1</PercentageResult></row>
<row _id="928"><id>928</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>4871</NumberResult><PercentageResult>6.4</PercentageResult></row>
<row _id="929"><id>929</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>102</NumberResult><PercentageResult>0.1</PercentageResult></row>
<row _id="930"><id>930</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>2145</NumberResult><PercentageResult>2.8</PercentageResult></row>
<row _id="931"><id>931</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>730</NumberResult><PercentageResult>1</PercentageResult></row>
<row _id="932"><id>932</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>486</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="933"><id>933</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>11</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="934"><id>934</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>16</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="935"><id>935</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>1</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="936"><id>936</id><FinancialYear>2012/13</FinancialYear><HBT>S08000024</HBT><HBTQF /><Laboratory>Edinburgh Royal Infirmary</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>5</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="937"><id>937</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Total number of smears</Results><ResultsQF>d</ResultsQF><NumberResult>29342</NumberResult><PercentageResult>100</PercentageResult></row>
<row _id="938"><id>938</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Unsatisfactory</Results><ResultsQF /><NumberResult>500</NumberResult><PercentageResult>1.7</PercentageResult></row>
<row _id="939"><id>939</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Negative</Results><ResultsQF /><NumberResult>26629</NumberResult><PercentageResult>92.3</PercentageResult></row>
<row _id="940"><id>940</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in squamous cells</Results><ResultsQF /><NumberResult>1029</NumberResult><PercentageResult>3.6</PercentageResult></row>
<row _id="941"><id>941</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Borderline change in endocervical cells</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="942"><id>942</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Low grade dyskaryosis</Results><ResultsQF /><NumberResult>839</NumberResult><PercentageResult>2.9</PercentageResult></row>
<row _id="943"><id>943</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (moderate)</Results><ResultsQF /><NumberResult>161</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="944"><id>944</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (severe)</Results><ResultsQF /><NumberResult>165</NumberResult><PercentageResult>0.6</PercentageResult></row>
<row _id="945"><id>945</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>High grade dyskaryosis (invasive)</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="946"><id>946</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Glandular Abnormality</Results><ResultsQF /><NumberResult>6</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="947"><id>947</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endocervical Adenocarcinoma</Results><ResultsQF /><NumberResult>2</NumberResult><PercentageResult>0</PercentageResult></row>
<row _id="948"><id>948</id><FinancialYear>2012/13</FinancialYear><HBT>S08000030</HBT><HBTQF /><Laboratory>Ninewells</Laboratory><LaboratoryQF /><Results>Endometrial or other malignancy</Results><ResultsQF /><NumberResult>3</NumberResult><PercentageResult>0</PercentageResult></row>
</data>
